Loading
A phase 3 trial of Sacituzumab tirumotecan, Doxorubicin, Paclitaxel / nab-paclitaxel in endometrial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) is a phase 3 interventional study registered as NCT06132958 by Merck Sharp & Dohme LLC, with 710 participants planned, started 2023-12-06 and due to reach its primary completion in 2028-01-10. Interventions recorded: Sacituzumab tirumotecan, Doxorubicin, Paclitaxel, Nab-paclitaxel, Rescue medications. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Endometrial cancer.
Shares Sacituzumab tirumotecan, Doxorubicin, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Paclitaxel / nab-paclitaxel.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Paclitaxel / nab-paclitaxel.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/